Globus Medical currently has an Earnings ESP of ... Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Globus Medical currently has an Earnings ESP of ... Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...

A study conducted by the Osservatorio Contract Logistics Gino Marchet reveals that while Italy's healthcare logistics sector ...

He has no past medical history, takes no regular medications ... should alert you to the possibility of a malignant aetiology, whereas stable and intermittent symptoms are more commonly associated ...

We report microelectrode data from the globus pallidus interna (GPi ... Dystonia Society UK, Action Medical Research, German National Academic Foundation. This was a retrospective analysis of ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $356.36 today based on a price of $86.88 for GMED at the time of writing.